CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 145 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.76 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,307 | +215.4% | 423 | -4.3% | 0.00% | – |
| Q1 2022 | $2,000 | 0.0% | 442 | 0.0% | 0.00% | – |
| Q4 2021 | $2,000 | 0.0% | 442 | 0.0% | 0.00% | – |
| Q3 2021 | $2,000 | 0.0% | 442 | 0.0% | 0.00% | – |
| Q2 2021 | $2,000 | 0.0% | 442 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | 0.0% | 442 | 0.0% | 0.00% | – |
| Q4 2020 | $2,000 | -50.0% | 442 | 0.0% | 0.00% | – |
| Q3 2020 | $4,000 | +100.0% | 442 | 0.0% | 0.00% | – |
| Q2 2020 | $2,000 | – | 442 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 442 | -21.6% | 0.00% | – |
| Q4 2019 | $2,000 | – | 564 | +1466.7% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 36 | -99.6% | 0.00% | – |
| Q1 2019 | $136,000 | +30.8% | 10,260 | -21.8% | 0.00% | – |
| Q4 2018 | $104,000 | -11.9% | 13,120 | +23.1% | 0.00% | – |
| Q3 2018 | $118,000 | -22.4% | 10,660 | -6.2% | 0.00% | – |
| Q2 2018 | $152,000 | – | 11,360 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |